Diabetic Nephropathy: A National Dialogue


Summary
The National Institute of Diabetes and Digestive and Kidney Diseases-supported Kidney Research National Dialogue (KRND) asked the scientific community to formulate and prioritize research objectives that would improve our understanding of kidney function and disease. Several high-priority objectives for diabetic nephropathy were identified in data and sample collection, hypothesis generation, hypothesis testing, and translation promotion. The lack of readily available human samples linked to comprehensive phenotypic, clinical, and demographic data remains a significant obstacle. With data and biological samples in place, several possibilities exist for using new technologies to develop hypotheses. Testing novel disease mechanisms with state-of-the-art tools should continue to be the foundation of the investigative community. Research must be translated to improve diagnosis and treatment of people. The objectives identified by the KRND provide the research community with future opportunities for improving the prevention, diagnosis, and treatment of diabetic nephropathy.

Kidney disease is a significant medical and public health problem (1). The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recently asked the community to identify research objectives that, if addressed, would improve our understanding of basic kidney function and aid in the prevention, treatment, and reversal of kidney disease. The Kidney Research National Dialogue (KRND) welcomed all interested parties to submit, discuss, and prioritize ideas via an interactive website. During the past 2 years, 1600 participants posted almost 300 ideas covering all areas of kidney disease.

Diabetic nephropathy (DN) is the largest single cause of ESRD in the United States and accounts for nearly 44% of the >115,000 newly affected individuals requiring dialysis each year (1). People with DN do poorly on dialysis, with high rates of infection, access failure, and cardiovascular complications. Of all the long-term complications of diabetes, nephropathy imposes the highest costs in terms of both dollars and human suffering. Despite aggressive management, the risk for ESRD in DN remains high. New management strategies and therapies are needed. The KRND identified several research objectives for DN that fall into four categories (Figure 1).

Data and Sample Collection
Lack of readily available human samples linked to comprehensive phenotypic, clinical, and demographic data remains a significant obstacle. The community proposed several ideas to encourage the collection of these resources for discovery science in DN.

Establish a Network of Biorepositories of Well Characterized Human Samples
A large amount of material (including DNA, urine, serum, and immortalized cells) is in storage from multiple clinical trials and genetic studies. Coordination of access to these samples should be initiated.

Collaborate with Large Health Organizations
Major efforts should be made to preconsent and obtain clinical data and biologic samples (including tissues) from people at risk for DN beginning early in the course of illness, taking advantage of large, coordinated care systems with electronic medical records. Correlation of assay results from these samples with longitudinal data are essential and would allow investigators to more fully understand the heterogeneity of clinical DN and identify patterns of disease that might otherwise be missed.

Partner with Transplant Surgeons and Urologists Who Perform Nephrectomies
Tissue samples from people who have kidneys removed for trauma or cancer should be retained. Samples of normal kidney tissue collected at the time of donor nephrectomy could be used as control material. Long-term follow-up of these donors and others who undergo nephrectomy would also be of considerable interest.

Leverage Ongoing and Completed Clinical Studies
Longitudinal studies of disease (e.g., Chronic Renal Insufficiency Cohort study, Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Study) provide a rich...
source of material coupled with comprehensive phenotyping. Immediate efforts should be made to consent individuals so that data and samples from these and future studies are available to the wider research community. Complication rates from kidney biopsies are low (2), thereby enhancing the practicability of people undergoing biopsies for research purposes.

**Hypotheses Generation**

With comprehensive data and biological samples in place, several possibilities exist for using new technologies to develop hypotheses.

**Define Key Genetic and Epigenetic Risk Factors**

Metabolic control alone does not fully predict an individual’s risk for diabetic complications (3). Identifying variants is a critical step in determining causality and defining the genetic and epigenetic architecture of human DN. Many of the ideas discussed in the KRND identify corollary issues to this fundamental objective, and there was strong support for using unbiased mapping strategies to achieve this goal.

**Determine Molecular Pathways**

The abundance of molecular pathways affected by diabetes presents not only the challenge of understanding complex interactions but also the opportunity of providing multiple and potentially complementary targets for drug development that can be tested using trial designs that are more representative of real-life clinical practice. Continued research into the underlying pathogenic mechanisms mediating diabetic complications should be highly encouraged.

**Analyze the Efficacy of Systems Biology to Discover New Pathways and Targets**

Systems biology aims to define the underlying regulatory principles in complex human diseases. Appropriate tools are needed to integrate genotyping information, RNA expression, promoter analysis, proteome expression, and metabolome profiles. This knowledge needs to be applied to clinical diabetes through better access and techniques for understanding human pathobiology.

**Hypothesis Testing**

Pursuing novel disease mechanisms with state-of-the-art tools should continue to be the foundation of our investigative community.

**Create “Humanized” Mice**

Although mouse models have many advantages, the human phenotype is difficult to faithfully replicate using candidate gene approaches. Future work should focus on developing “humanized” mice, in which loci associated with human diabetic complications are knocked in. The technology for recapitulating these human variants in mice will be one of the few options for direct functional testing in mammals (4).

**Define a Role for Nonmammalian Systems**

Nonmammalian model organisms are underused. These simple organisms permit ease of genetic manipulation, rapid throughput, genome-wide screens, and precise measurement of phenotypes (5). More should be done with large-scale screens that require establishing congruencies between model organisms and mammals.

**Develop Novel Technologies**

There is an expectation that imaging, systems biology, and bioinformatics will identify new areas of clinical relevance in DN. If that happens, scientists will require new levels of training and robust collaborations.

**Translation Promotion**

The community provided several ideas to enhance diagnosis and treatment of DN.
Develop Biomarkers

The lack of robust and dynamic biomarkers for molecular classification, risk stratification, morphologic prediction, and alternative outcomes is a major gap in the field, contributing to the high cost and long duration of clinical trials. Discovery of biomarkers that are sensitive to the rate of disease progression would allow rapid screening of potential therapeutics and preselection of clinical trial participants.

Identify New Ways to Foster Translation

Mechanisms should be established to support development of drugs and biologics that will not be pursued by industry. The expansion of existing preclinical programs and the establishment of clinical trial networks would allow potential therapies to be developed and tested in early phase I and II trials that could lead to phase III trials.

Analyze How “Omic” Medicine May Alter Patient Care

Personalized medicine is limited by the number of therapies and the “omic” approaches used to identify people who would be responsive to a particular therapy. Nevertheless, work in this area could have significant potential for identifying new therapeutic targets and improved applications of existing therapies.

Conclusion

Research efforts over the past several years generally relied on candidate approaches, predicated on individual hypotheses and often tested exclusively in cell culture or animal models. Although these efforts led to interesting biology, more progress needs to be made in understanding key mechanisms in human DN. Progress toward this end is hampered by the relative paucity of longitudinally phenotyped individuals and biologic samples to provide the necessary resources to stimulate innovative clinical, translational, and basic research. In oncology, by contrast, the ubiquitous availability of tissue has fueled substantial advances in understanding molecular pathogenesis and developing new therapies. The KRND proposes to discover critical candidates, identify regulatory pathways, generate novel models for preclinical work, and develop biomarkers with clinical utility so DN outcomes can be improved.

Acknowledgments

The KRND was developed and implemented by NIDDK/Division of Kidney, Urologic, and Hematologic Diseases staff and was directed by Dr. Krystyna Rys-Sikora. The DN topic was facilitated by Drs. Chris Ketchum and Mike Flessner. Visit the KRND (http://www2.niddk.nih.gov/KUH/KUHHome/) or the NIDDK-supported Diabetic Complications Consortium (http://www.diacomp.org/) for full details or to post comments about this review.

Disclosures

Dr. Breyer is an employee of Eli Lilly. The remaining coauthors had no disclosures to provide.

References


All authors contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.03640413/-/DCSupplemental.
Kidney Research National Dialogue

Breyer, Matthew D.
Biotherapeutics Discovery Research
Lilly Research Laboratories
Indianapolis, IN

Coffman, Thomas M.
Department of Medicine
Duke University and VA Medical Centers
Durham, NC

Flessner, Michael F.
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Bethesda, MD 20892

Fried, Linda F.
Renal Section
VA Pittsburgh Healthcare System and
Departments of Medicine and Epidemiology
University of Pittsburgh
Pittsburgh, PA

Harris, Raymond C.
Department of Medicine
Vanderbilt University
Nashville, TN

Ketchum, Christian J.
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Bethesda, MD 20892

Kretzler, Matthias
Department of Internal Medicine
University of Michigan Medical School
Ann Arbor, MI

Nelson, Robert G.
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Phoenix, AZ

Sedor, John R.
Department of Medicine
Case Western Reserve University
Cleveland, OH

Susztak, Katalin
Department of Medicine
University of Pennsylvania
Philadelphia, PA